These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 26145175)
1. MicroRNA-101 Suppresses Tumor Cell Proliferation by Acting as an Endogenous Proteasome Inhibitor via Targeting the Proteasome Assembly Factor POMP. Zhang X; Schulz R; Edmunds S; Krüger E; Markert E; Gaedcke J; Cormet-Boyaka E; Ghadimi M; Beissbarth T; Levine AJ; Moll UM; Dobbelstein M Mol Cell; 2015 Jul; 59(2):243-57. PubMed ID: 26145175 [TBL] [Abstract][Full Text] [Related]
2. NRF3-POMP-20S Proteasome Assembly Axis Promotes Cancer Development via Ubiquitin-Independent Proteolysis of p53 and Retinoblastoma Protein. Waku T; Nakamura N; Koji M; Watanabe H; Katoh H; Tatsumi C; Tamura N; Hatanaka A; Hirose S; Katayama H; Tani M; Kubo Y; Hamazaki J; Hamakubo T; Watanabe A; Murata S; Kobayashi A Mol Cell Biol; 2020 Apr; 40(10):. PubMed ID: 32123008 [TBL] [Abstract][Full Text] [Related]
3. The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer. Thaler S; Thiede G; Hengstler JG; Schad A; Schmidt M; Sleeman JP Int J Cancer; 2015 Aug; 137(3):686-97. PubMed ID: 25530422 [TBL] [Abstract][Full Text] [Related]
4. Roles of estrogen receptor and p21(Waf1) in bortezomib-induced growth inhibition in human breast cancer cells. Maynadier M; Shi J; Vaillant O; Gary-Bobo M; Basile I; Gleizes M; Cathiard AM; Wah JL; Sheikh MS; Garcia M Mol Cancer Res; 2012 Nov; 10(11):1473-81. PubMed ID: 22964432 [TBL] [Abstract][Full Text] [Related]
5. Estrogen-dependent gene transcription in human breast cancer cells relies upon proteasome-dependent monoubiquitination of histone H2B. Prenzel T; Begus-Nahrmann Y; Kramer F; Hennion M; Hsu C; Gorsler T; Hintermair C; Eick D; Kremmer E; Simons M; Beissbarth T; Johnsen SA Cancer Res; 2011 Sep; 71(17):5739-53. PubMed ID: 21862633 [TBL] [Abstract][Full Text] [Related]
6. Proteasome inhibition represses ERalpha gene expression in ER+ cells: a new link between proteasome activity and estrogen signaling in breast cancer. Powers GL; Ellison-Zelski SJ; Casa AJ; Lee AV; Alarid ET Oncogene; 2010 Mar; 29(10):1509-18. PubMed ID: 19946334 [TBL] [Abstract][Full Text] [Related]
7. MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib. Jagannathan S; Vad N; Vallabhapurapu S; Vallabhapurapu S; Anderson KC; Driscoll JJ Leukemia; 2015 Mar; 29(3):727-38. PubMed ID: 25234165 [TBL] [Abstract][Full Text] [Related]
9. Blocking Cancer Growth with Less POMP or Proteasomes. Goldberg AL; Zhao J; Collins GA Mol Cell; 2015 Jul; 59(2):143-5. PubMed ID: 26186288 [TBL] [Abstract][Full Text] [Related]
10. Antitumor effects of proteasome inhibition in anaplastic thyroid carcinoma. Altmann A; Markert A; Askoxylakis V; Schöning T; Jesenofsky R; Eisenhut M; Haberkorn U J Nucl Med; 2012 Nov; 53(11):1764-71. PubMed ID: 23055533 [TBL] [Abstract][Full Text] [Related]
11. Anti-tumor activity of the proteasome inhibitor BSc2118 against human multiple myeloma. Zang M; Li Z; Liu L; Li F; Li X; Dai Y; Li W; Kuckelkorn U; Doeppner TR; Hermann DM; Zhou W; Qiu L; Jin F Cancer Lett; 2015 Oct; 366(2):173-81. PubMed ID: 26116344 [TBL] [Abstract][Full Text] [Related]
12. Increased expression and altered subunit composition of proteasomes induced by continuous proteasome inhibition establish apoptosis resistance and hyperproliferation of Burkitt lymphoma cells. Fuchs D; Berges C; Opelz G; Daniel V; Naujokat C J Cell Biochem; 2008 Jan; 103(1):270-83. PubMed ID: 17516511 [TBL] [Abstract][Full Text] [Related]
13. The proteasome maturation protein POMP increases proteasome assembly and activity in psoriatic lesional skin. Zieba BA; Henry L; Lacroix M; Jemaà M; Lavabre-Bertrand T; Meunier L; Coux O; Stoebner PE J Dermatol Sci; 2017 Oct; 88(1):10-19. PubMed ID: 28728908 [TBL] [Abstract][Full Text] [Related]
14. The Nuclear Factor (Erythroid-derived 2)-like 2 and Proteasome Maturation Protein Axis Mediate Bortezomib Resistance in Multiple Myeloma. Li B; Fu J; Chen P; Ge X; Li Y; Kuiatse I; Wang H; Wang H; Zhang X; Orlowski RZ J Biol Chem; 2015 Dec; 290(50):29854-68. PubMed ID: 26483548 [TBL] [Abstract][Full Text] [Related]
15. Bortezomib induces apoptosis of endometrial cancer cells through microRNA-17-5p by targeting p21. Shen Y; Lu L; Xu J; Meng W; Qing Y; Liu Y; Zhang B; Hu H Cell Biol Int; 2013 Oct; 37(10):1114-21. PubMed ID: 23716467 [TBL] [Abstract][Full Text] [Related]
16. Synergistic interaction between the novel histone deacetylase inhibitor ST2782 and the proteasome inhibitor bortezomib in platinum-sensitive and resistant ovarian carcinoma cells. Gatti L; Benedetti V; De Cesare M; Corna E; Cincinelli R; Zaffaroni N; Zunino F; Perego P J Inorg Biochem; 2012 Aug; 113():94-101. PubMed ID: 22717676 [TBL] [Abstract][Full Text] [Related]
17. A proteomic analysis of p53-independent induction of apoptosis by bortezomib in 4T1 breast cancer cell line. Yerlikaya A; Okur E; Baykal AT; Acılan C; Boyacı I; Ulukaya E J Proteomics; 2015 Jan; 113():315-25. PubMed ID: 25305590 [TBL] [Abstract][Full Text] [Related]
18. Melatonin as a proteasome inhibitor. Is there any clinical evidence? Vriend J; Reiter RJ Life Sci; 2014 Oct; 115(1-2):8-14. PubMed ID: 25219883 [TBL] [Abstract][Full Text] [Related]
19. Cap-dependent mRNA translation and the ubiquitin-proteasome system cooperate to promote ERBB2-dependent esophageal cancer phenotype. Issaenko OA; Bitterman PB; Polunovsky VA; Dahlberg PS Cancer Gene Ther; 2012 Sep; 19(9):609-18. PubMed ID: 22767218 [TBL] [Abstract][Full Text] [Related]
20. Combination therapy targeting ectopic ATP synthase and 26S proteasome induces ER stress in breast cancer cells. Chang HY; Huang TC; Chen NN; Huang HC; Juan HF Cell Death Dis; 2014 Nov; 5(11):e1540. PubMed ID: 25429617 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]